Join us at the 13th Korea International Pharmaceutical & Bio-Pharma Exhibition on April 18th-21st. Our Director Business Development, Gaurav Kanoja, PhD, will give a presentation on Avacc 2®, our quadrivalent vaccine candidate against Hand Foot and Mouth Disease (HFMD).
(More details to follow).
Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow Appointment for three years at the Strathclyde Institute of Pharmacy and Biomedical Sciences Schijns published over 120 scientific papers in the field of immunology and adjuvants Bilthoven, The Netherlands, 23 February 2023 – Intravacc, a world leader in…
• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection
• Global incidence rate of this sexual transmitted disease is at 87 million infections per year
• OMV technology is a powerful tool to induce protective systemic and mucosal immunity
• Data published in the peer reviewed journal MSphere of the American Society of Microbiology
